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Abstract Despite the well-established antitumor activity
of CD1d-restricted invariant natural killer T lymphocytes
(iNKT), their use for cancer therapy has remained chal-
lenging. This appears to be due to their strong but short-
lived activation followed by long-term anergy after a single
administration of the CD1d agonist ligand alpha-galacto-
sylceramide (aGC). As a promising alternative, we obtained
sustained mouse iNKT cell responses associated with pro-
longed antitumor effects through repeated administrations
of tumor-targeted recombinant sCD1d-antitumor scFv
fusion proteins loaded with aGC. Here, we demonstrate that
CD1d fusion proteins bound to tumor cells via the antibody
fragment specific for a tumor-associated antigen, efficiently
activate human iNKT cell lines leading to potent tumor
cell lysis. The importance of CD1d tumor targeting was
confirmed in tumor-bearing mice in which only the specific
tumor-targeted CD1d fusion protein resulted in tumor
inhibition of well-established aggressive tumor grafts. The
therapeutic efficacy correlated with the repeated activation
of iNKT and natural killer cells marked by their release of
TH1 cytokines, despite the up-regulation of the co-inhibi-
tory receptor PD-1. Our results demonstrate the superiority
of providing the superagonist aGC loaded on recombinant
CD1d proteins and support the use of aGC/sCD1d-antitu-
mor fusion proteins to secure a sustained human and mouse
iNKT cell activation, while targeting their cytotoxic activity
and cytokine release to the tumor site.
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Introduction
Human Va24-invariant natural killer T lymphocytes (iNKT),
and their murine counterparts Va14-iNKT cells, represent a
particular sublineage of T lymphocytes activated by self- and
microbial-derived glycolipids in the context of the mono-
morphic MHC-related molecule CD1d. Their importance in
the transactivation of innate and adaptive immune responses
has been extensively described [1, 2], as well as their pro-
tective or pathological role in various conditions [3]. In par-
ticular, their antitumor activity has been well documented in a
number of mouse tumor models [4–6], and several clinical
observations also indicate their protective role against cancer
progression. Furthermore, low numbers and impaired pro-
liferative capacity of iNKT cells were reported in cancer
patients compared to normal donors [7, 8], which in some
studies were correlated with poor clinical outcome [9, 10].
These preclinical and clinical observations have prompted
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testing of iNKT cell-directed therapies, mainly through their
strong activation by the synthetic glycosphingolipid CD1d
ligand, alpha-galactosylceramide (aGC) [11–13]. Phase I
clinical trials involving the autologous transfer of aGC-
pulsed monocyte-derived dendritic cells (moDC) were
conducted in patients with different types of cancer [4, 11,
13–16]. No severe adverse effects were seen and the transient
expansion and activation of iNKT cells, obtained in non-
small-cell lung cancer (NSCLC) and head and neck squa-
mous cell cancer (HNSCC) patients, correlated with some
clinical benefit. Unfortunately, however, iNKT cell-mediated
tumor immunotherapy has been limited by the short-lived
cytokine response of iNKT cells to aGC stimulation, fol-
lowed by a long-term anergy [4, 17, 18]. Recently, we have
instead showed that sustained mouse iNKT cell responses
could be induced by repeated stimulations with recombinant
aGC-loaded sCD1d fusion proteins [19]. This prolonged
responsiveness of iNKT cells resulted in potent antitumor
activity when CD1d was targeted to the tumor site by its
fusion to an anti-HER2 antitumor antibody fragment [19]. In
the present study, recombinant CD1d proteins are shown to
expand and activate human iNKT cells without the need of
antigen-presenting cells (APCs). Importantly, we show that
human iNKT cells exhibit a potent direct cytotoxicity only
against cancer cells coated with the specific sCD1d-antitumor
scFv fusion protein. The importance of CD1d tumor targeting
to promote sustained activation of iNKT cells and prolonged
tumor inhibition is further characterized in mice in thera-
peutic settings.
Materials and methods
Mice and human samples
Female mice C57BL/6J (B6) 6–8 weeks old (Harlan, Zeist,
Holland) were maintained in specific pathogen-free con-
ditions. All animal experiments were conducted according
to institutional guidelines and under an authorization
delivered by the Swiss veterinary department. Fresh human
PBMC were obtained from healthy donor blood, isolated
by density centrifugation using Lymphoprep (Axis-Shield
PoC AS, Norway).
Tumor cell lines and human iNKT cell lines and clones
The murine colon carcinoma MC-38 cell line transfected with
human CEA (MC38-CEA) was a kind gift from J. Primus
[20]. The human cell lines KATO III (gastric carcinoma) and
SK-BR-3 (breast carcinoma) were obtained from the ATCC.
The human B lymphoma cell line C1R stably transfected with
human CD1d was used as APC. Alternatively, moDCs were
generated as described by Shao et al. [21]. Human iNKT cell
lines were established starting with fresh PBMC from healthy
donors cultured with aGC (100 ng/ml) or aGC/sCD1d pro-
teins (40 lg/ml) in RPMI medium with 8 % human serum,
recombinant IL-2 (20 U/ml) and IL-7 (10 ng/ml). Human
iNKT cell clones had been previously generated by limiting
dilution after sorting from peripheral blood lymphocytes
(PBLs) of healthy donors by anti-CD3, anti-Va24, and anti-
Vb11 mAbs staining [22].
Reagents and antibodies
The aGC analog KRN7000 (Alexis Biochemicals Corp) was
dissolved in PBS-0.5 % Tween-20. Cytokine levels were
measured either individually by ELISA (ELISA ready-set-
go, eBiosciences), or as multiple cytokine measurements
using BD Cytometric Bead Array kit TH1/TH2/TH17 (CBA,
BD Biosciences). All fluorochrome-labeled antibodies were
purchased from Becton–Dickinson (BD Biosciences) or
eBiosciences. The humanized mAbs anti-HER2 Herceptin
(Trastuzumab) was from Roche Ltd and anti-CEA (X4) from
Ciba-Geigy [23]. Cells were analyzed with a FACSCalibur,
FACSCanto or LSRII (BD Biosciences) and the acquired data
were processed using FlowJo software (Tree Star Inc.).
Recombinant CD1d fusion proteins
Genetic fusion of mouse b2 microglobulin (b2 m) with the
soluble part of mouse CD1d (sCD1d) has been described
previously [19]. In the original pEAK8-b2m-sCD1d-anti-
HER2-6xHIS construct, the anti-HER2 scFv located between
the Gly-Ser spacer and the 6xHIS was replaced by the anti-
CEA scFv MFE23 (kindly provided by R.H. Begent [24]).
Recombinant CD1d fusion proteins produced by transient
transfection of the human cell line HEK293-EBNA (Cellular
Biotechnology Laboratory, EPFL, Switzerland) were puri-
fied and loaded with aGC as previously reported [19] (Fig.
S1). The CD1d tetramer was developed by engineering a
BirA consensus sequence at the C-terminus of the soluble
mouse CD1d protein. The CD1d monomer was biotinylated
by the BirA enzyme (Avidity, Denver, CO), and after loading
with aGC, it was tetramerized on streptavidin-PE (Invitro-
gen) using a molar ratio of 4:1.
In vitro proliferation
Human iNKT cells were labeled with 1 lM CFSE for
6 min at 37 C and washed three times. Labeled iNKT
cells were incubated in a 12-well plate at 1 9 106 cells/ml
in RPMI with 8 % HS, 30 U/ml IL-2, and 10 ng/ml IL-7 at
37 C. iNKT cells were stimulated with either 8 9 105
irradiated aGC-loaded C1R-CD1d, plastic-coated sCD1d
fusion proteins (40 lg), or 200 ng/ml aGC. The dilution of
CFSE was analyzed by flow cytometry.
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iNKT cell cytotoxicity
For chromium release experiments, iNKT clones, CD4? or
double negative (DN), were thawed the day before and kept
overnight in RPMI 8 %HS supplemented with recombinant
IL-2 (150 U/ml) and IL-7 (10 ng/ml). On the day of the
experiment, target cells were labeled with 51Cr for 1 h at
37 C and washed three times in medium before incubation
(103 cells per well) in 96 V-bottom well plates either
with effector cells at an E:T ratio of 10:1 and different
concentration of CD1d-recombinant molecules, or in the
presence of different E:T ratios and a fixed concentration of
CD1d-recombinant molecules (10 lg/ml). Supernatants
were collected after 4 h of incubation at 37 C, and
released radioactivity was measured in a c-counter. For
Annexin V analysis, 2 9 105 NKT cells were incubated
with 1 9 104 tumor cells in the presence of either aGC/
sCD1d-antitumor scFv at 10 lg/ml in RPMI 8 % human
serum or 5 9 104 aGC/C1R-CD1d cells or 5 9 104 aGC/
moDCs for 4 h at 37 C. After incubation, tumor cells and
APCs were analyzed using Annexin V kit (BD Pharmin-
gen) and CD1d-tetramer-positive iNKT cells were stained
for CD107a and intracellular content of IFNc and TNFa.
Antitumor therapy
Mice were grafted s.c. in the right flank with 7 9 105
MC38-CEA cells. When all tumors were palpable, mice
were treated i.v. with 200 ll of either PBS alone, equi-
molar amounts of aGC (0.4 lg), aGC/sCD1d (25 lg), or
aGC/CD1d-antitumor scFv fusion proteins (40 lg). Sys-
temic treatment was repeated at 3- to 4-day intervals. Mean
tumor volume measured every 2 days was calculated using
the following formula: (length 9 width 9 thickness)/2.
Statistical analysis
Results are expressed as mean ± SEM. Statistical signifi-
cance between the groups was determined with student’s t test
or one-way -ANOVA test with Bonferroni correction
(GraphPad Prism, GraphPad software). Tumor progression
statistics were calculated with two-way ANOVA test with
Bonferroni correction (GraphPad Prism, GraphPad software).
Results
Human iNKT cells efficiently proliferate
in the presence of aGC-loaded CD1d protein
To validate the usefulness of soluble recombinant CD1d
proteins for clinical immunotherapy, we investigated the
reactivity of human iNKT cells to mouse aGC/sCD1d or
aGC/sCD1d-antitumor scFv proteins. Irrespectively of
whether fused or not to an antitumor scFv fragment, all
sCD1d fusion proteins in solution were able to expand
iNKT cell lines from freshly isolated human PBMC. The
kinetics of expansion was similar to that observed fol-
lowing exposure to free aGC (Fig. 1a), with approximately
40 % iNKT cells on day 7 and 60 % on day 14 of culture.
All iNKT cell lines, whether expanded with free aGC or
aGC-loaded sCD1d fusion proteins, retained the same
subset composition, with a majority of DN and a minority
of CD8? iNKT cells (Fig. 1b). Importantly, recombinant
aGC/sCD1d proteins could directly expand pure iNKT cell
populations, as seen by CFSE dilution (Fig. 1c) and
increased numbers of iNKT cells over 5 days of culture
(data not shown), whereas the addition of irradiated APCs
was required for free aGC to induce iNKT cell prolifera-
tion. These data indicate that aGC-loaded recombinant
CD1d proteins directly trigger the semi-invariant TCR of
human iNKT cells, and thus represent a promising tool for
rapid and potent expansion of human iNKT cells from
patients for subsequent adoptive cell transfer.
Soluble CD1d proteins directly activate human iNKT
cell clones without requirement for APCs
As suggested by the expansion of human iNKT cells, aGC-
loaded sCD1d proteins did not require the presence of
APCs and were sufficient to activate human iNKT cell
clones to release IFNc after 18-h incubation (Fig. 2a). In
contrast, aGC as a free drug was unable to activate iNKT
cell clones in the absence of APCs (Fig. 2a) and required
the presence of CD1d-expressing cells such as the human
lymphoma C1R transfected with CD1d (Fig. 2b). These
data fully established that the activation of human iNKT
cells by soluble CD1d proteins did not result from the
transfer of aGC to endogenously expressed CD1d, but
rather from the direct TCR triggering by the soluble fusion
proteins. As shown for iNKT cell proliferation, plastic-
coated sCD1d proteins were even more efficient than sol-
uble proteins in inducing iNKT cell clones to release a
panel of cytokines such as IFNc, TNFa, IL-2, and IL-4
(Fig. 2b). Still, when compared to aGC loaded on C1R-
CD1d APCs, sCD1d proteins remained about threefold
weaker in activating iNKT cells, likely resulting from the
lack of adhesion mechanisms and molecular aggregation
provided by cell–cell interaction.
Human iNKT cells efficiently kill tumor cells only
when coated with the sCD1d-antitumor fusion protein
In view of the rare expression of CD1d on tumor cells, the
direct cytotoxicity of iNKT cells against tumors has been
disregarded, and instead, the immediate antitumor activity
Cancer Immunol Immunother (2013) 62:747–760 749
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of iNKT cells was shown to be largely mediated by the
transactivation of natural killer cells [5, 19, 25]. However,
direct cytotoxicity of human iNKT cells has been well
demonstrated, especially against CD1d-expressing leuke-
mia in vitro and in vivo [26, 27]. Here, we show that the
killing capacity of human iNKT cells can be extended
Fig. 1 Expansion of human iNKT cell lines by aGC/sCD1d proteins.
a PBMCs from healthy donors were stimulated with medium alone,
aGC (100 ng/ml) or aGC/sCD1d protein (10 lg/ml). Frequency of
iNKT cells in total PBMC was assessed as CD1d-tetramer?CD3? at
day 0, 7, and 14 of culture. Results are shown as mean ± SEM of four
donors. b Distribution of human iNKT cell subsets ex vivo and after
14 days of culture as described in a. Dots represent percentages of
CD4, CD8, and DN iNKT cells in total CD1d-tetramer?CD3? from
normal individuals or expanded cell lines, and bars show mean ±
SEM. c CFSE-labeled iNKT cells were incubated for 5 days with the
different stimuli, and CFSE dilution was analyzed by FACS on gated
CD1d-tetramer?CD3? cells. Left panel illustrates CFSE fluorescence
in iNKT cells on day 5 of culture. Right panel shows the kinetic of
CFSE dilution as the fold increase of CFSElow iNKT cells. Results
shown are representative of three independent experiments
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against CD1d-negative tumor cells by their coating with
aGC/CD1d-antitumor scFv fusion proteins. Two human
tumor cell lines were selected based on their expression of
HER2 and/or CEA (Fig. 3a). The pancreatic tumor cell line
KATO III expresses both HER2 and CEA, as shown by the
binding of the specific antibodies, as well as of the corre-
sponding sCD1d-anti-HER2 and the newly developed
sCD1d-anti-CEA fusion proteins (Fig. S1). In contrast, the
breast cancer cell line SKBR-3 highly expresses HER2 but
is negative for CEA, which provided the possibility of
evaluating targeted versus untargeted iNKT cell-mediated
cytotoxicity. After 4-h incubation with iNKT cells, tumor
cells were killed only when coated with the relevant
sCD1d-scFv fusion proteins. Indeed, KATO III tumor cells
Fig. 2 Human iNKT cells are directly activated by recombinant
aGC/sCD1d proteins. a iNKT cell clones (105) were incubated for
18 h with aGC (100 ng/ml) or aGC/sCD1d proteins in solution
(10 lg/ml). Graph shows the level of IFNc in the supernatant as
the mean ± SEM of three different human iNKT cell clones.
***P \ 0.001. b Activation of iNKT cells by aGC/sCD1d proteins
or aGC-pulsed APCs. Human iNKT cell clones (105) were incubated
with no stimulus, with plastic-coated aGC/sCD1d proteins (10 lg) or
with the B-cell lymphoma cell line C1R-CD1d (5 9 104) pulsed or
not with aGC. After 24 h, cytokines were measured in supernatants
by CBA. *P \ 0.01**P \ 0.005, ***P \ 0.001, ****P \ 0.0001
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Fig. 3 Human iNKT cells efficiently kill tumor cells only when
coated with the aGC/sCD1d-antitumor fusion protein. a Expression of
HER2 and CEA by KATO III and SKBR3 human tumor cells
revealed either by the anti-HER2 (Herceptin) and anti-CEA (X4)
mAbs (upper panels), or by the binding of sCD1d-anti-CEA and
sCD1d–anti-HER2 fusion proteins, revealed by FITC-labeled anti-
CD1d (lower panels). b 51Cr release assay after 4-h incubation of
iNKT cell clones with the tumor cell lines described in a. Graph
curves show percent killing of KATO III (left panel) and SKBR-3
cells (right panel) with decreasing effector-to-target ratio (E/T) with
2 9 103 target tumor cells and 10 lg/ml of sCD1d fusion proteins.
c Panels show percent killing of KATO III (left) and SKBR-3 cells
(right) with decreasing concentrations of sCD1d fusion proteins at an
E/T ratio of 10/1. Results shown are representative of three
independent experiments
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co-expressing HER2 and CEA were killed in the presence
of either of the two aGC/sCD1d-antitumor proteins
(Fig. 3b, left panel), with 40 and 60 % of tumor cells killed
at an E/T ratio of 30/1 and 10 lg/ml of aGC/sCD1d-anti-
HER2 and aGC/sCD1d-anti-CEA fusion proteins, respec-
tively. In contrast, the SKBR-3 tumor cells expressing only
HER2 were exclusively killed when incubated with the
aGC/sCD1d-anti-HER2 protein (Fig. 3b, right panel), with
80 % of cells eliminated, while co-incubation with the
aGC/sCD1d-anti-CEA protein resulted in only background
51Cr release similar to medium alone. At an E/T ratio of
10/1 (Fig. 3c), 20 % targeted killing of KATO III (left
panel) and 50 % killing of SKBR-3 (right panel) tumor
cells was still obtained with 1 lg/ml (13 nM) of HER2 and/
or CEA-targeted CD1d fusion proteins, demonstrating the
sensitivity of this approach. All iNKT cell clones tested in
cytotoxic assays were CD4? or DN and showed similar
capacity of tumor-targeted cell killing.
Activated iNKT cells exhibit poor bystander
cytotoxicity and selectively kill CD1d-positive target
cells
In addition to 51Cr release experiments, the killing of
SKBR3 tumor cells was evidenced by their Annexin V?
7-AAD- profile, while the state of iNKT cell activation
was evaluated by CD107a expression, and secretion of
TNFa and IFNc (Fig. 4). After 4-h incubation with human
iNKT cells, an average of 60 % of SKBR3 tumor cells was
apoptotic when incubated with the tumor-targeted aGC/
sCD1d-anti-HER2 fusion protein, while there was a similar
background of tumor cell death with the untargeted aGC/
sCD1d-anti-CEA or with unstimulated iNKT cells
(Fig. 4a). Interestingly, when instead of recombinant CD1d
proteins, iNKT cells and SKBR-3 tumor cells were co-
incubated with aGC-pulsed C1R-CD1d cells or moDCs,
less than 20 % of SKBR3 cells became Annexin V positive
(Fig. 4a), although the percentages of CD107a, IFNc and
TNFa-positive iNKT cells (Fig. 4b, c) were similar after
incubation with the tumor-targeted aGC/sCD1d-anti-HER2
protein or with aGC/C1R-CD1d cells. The iNKT cell
activation was slightly weaker in the presence of aGC/
moDCs (Fig. 4b, c), likely resulting from their hundred
times lower CD1d expression than the C1R-CD1d trans-
fectant. In addition, the state of activation of iNKT cells
incubated with the aGC/sCD1d-anti-CEA did not differ
from unstimulated iNKT cells (Fig. S2). In conclusion, the
similar percentages of activated iNKT cells stimulated by
aGC-pulsed APCs or by tumor-targeted aGC/sCD1d-anti-
HER2 protein did not correlate with a similar killing of
SKBR3 tumor cells, but rather with the concomitant
elimination of the aGC/APCs, as shown by, respectively,
26 and 36 % of Annexin V? aGC/C1R-CD1d and aGC/
moDCs (Fig. 4a). Altogether, these data further confirmed
the requirement of CD1d on the surface of the target cell
for efficient killing, whether naturally expressed on the
surface or bound via its fusion to an antitumor scFv frag-
ment. The activation of iNKT cells by tumor-targeted
CD1d molecules was also evidenced by their cytokine
content (Fig. 4c). Indeed, in the presence of SKBR3 tumor
cells coated with aGC/sCD1d-anti-HER2, about half of
iNKT cells was positive for TNFa and IFNc, while no
intracellular cytokines were detected in the presence of the
irrelevant aGC/sCD1d-anti-CEA fusion protein. Alto-
gether, these results support the relevance of sCD1d-anti-
tumor fusion proteins for cancer therapy, as seen by the
strong activation of human iNKT cells, revealed by direct
tumor cytotoxicity and cytokine release.
In vivo targeting of aGC-loaded CD1d proteins
to the tumor site is required for prolonged iNKT
cell-mediated tumor inhibition
The importance of targeting aGC/sCD1d fusion proteins to
the tumor was further investigated in C57BL/6 mice graf-
ted with the MC38 colon carcinoma cell line stably trans-
fected with human CEA (MC38-CEA). Mice with
established tumors ([100 mm3) were treated either with
aGC/sCD1d-anti-CEA fusion protein (Fig. S1), aGC alone,
untargeted aGC/sCD1d or aGC/sCD1d-anti-HER2 fusion
proteins. After a total of six injections given over 3 weeks,
all mice treated with aGC/sCD1d-anti-CEA protein
retained small tumors barely exceeding 200 mm3, and
hence 60 % smaller than in untreated animals (700 mm3)
(Fig. 5a). In marked contrast, aGC alone and untargeted
sCD1d were unable to inhibit tumor growth. The require-
ment of tumor-targeted CD1d treatment to achieve a
therapeutic effect was best demonstrated in the mice trea-
ted with the irrelevant aGC/sCD1d-anti-HER2 fusion
protein, as all animals had fast tumor growth. The pro-
longed reactivity of iNKT cells was tested in the spleen by
the detection of ex vivo IFNc production 1 h after the sixth
injection. After repeated injections of aGC, only few iNKT
cells still produced IFNc, confirming the induction of
anergy upon repetitive stimulations (Fig. 5b) [18, 19].
Similarly, no significant IFNc was detected after untar-
geted aGC/sCD1d and irrelevant aGC/sCD1d-anti-HER2
treatments, though in this case likely resulting from a weak
activation of iNKT cells rather than anergy. In contrast,
15 % of spleen iNKT cells isolated from mice treated with
tumor-targeted aGC/sCD1d-anti-CEA were positive for
IFNc, which correlated with the fact that antitumor activity
was exclusively obtained in this group. Although tumor-
infiltrating iNKT cells were too few to be functionally
analyzed, the prolonged reactivity of iNKT cells only in the
spleens of mice treated with tumor-targeted fusion protein
Cancer Immunol Immunother (2013) 62:747–760 753
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suggested that these cells had been repeatedly activated at
the tumor site. In view of previous studies that attributed
aGC-induced iNKT cell anergy to the up-regulation of the
co-inhibitory receptor programmed death-1 (PD-1) [28,
29], we tested its expression level on spleen iNKT cells
(Fig. 5c). Strikingly, PD-1 expression was up-regulated not
only on the vast majority of iNKT cells after six injections
of aGC alone, but also after repeated injections of
recombinant aGC/sCD1d proteins, including iNKT cells
activated by the tumor-targeted aGC/sCD1d-anti-CEA
Fig. 4 Activated iNKT cells kill aGC/sCD1d-loaded tumor cells as
well as CD1d-positive APCs. a Apoptosis of SKBR3 tumor cells or
APCs after 4-h incubation with iNKT cell clones, in the presence of
aGC/sCD1d-CEA, aGC/sCD1d-HER2, aGC-pulsed C1R-CD1d cells,
or aGC-pulsed moDCs. Results are shown as percentages of Annexin
V? 7AAD- cells gated on HER2? SKBR-3 cells, CD20? C1R-CD1d,
or CD11c? moDCs, after subtracting the respective backgrounds
obtained with unstimulated iNKT cells. **P \ 0.005. b Cytotoxic
activity of iNKT cells in the same experiment described in a was
determined by assessing CD107a expression on the CD3?CD1d-
tetramer? effector cells. ***P \ 0.001. c The activation state
of iNKT cells was also evaluated by ICS for IFNc and TNFa.
The unstimulated group consists of the pooled data of iNKT
cells incubated with unpulsed C1R-CD1d cells or moDCs.
****P \ 0.0001 between all groups
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protein (Fig. 5b). Therefore, increased PD-1 expression did
not correlate with the state of unresponsiveness of iNKT
cells. At this point, it is interesting to mention that the
majority of human iNKT cells were found positive for PD-
1 expression when analyzed ex vivo in normal donor
PBMCs (Fig. S3), likely resulting from previous in vivo
stimulations. These observations suggest that PD-1 up-
regulation on mouse and human iNKT cells is rather a
marker of activation and is not in itself sufficient to
mediate iNKT cell anergy.
The prolonged reactivity of iNKT and NK cells
to repeated stimulations is optimized by tumor bound
CD1d proteins
The requirement for CD1d tumor targeting to provide
sustained reactivity of iNKT despite PD-1 up-regulation
was further characterized. As already reported [18, 19], a
single injection of aGC induced a fast and potent activation
of iNKT cells, as revealed by the presence of 40 % splenic
iNKT cells producing IFNc (Fig. 6a). However, after three
injections of aGC and despite similar numbers of iNKT
cells (data not shown), only 12 % of iNKT cells still pro-
duced IFNc (Fig. 6a), confirming the induction of anergy
upon repetitive stimulations [18, 19]. In contrast, 25 % of
iNKT cells from MC-38-CEA tumor-bearing mice treated
with aGC/sCD1d-anti-CEA fusion protein still produced
IFNc (Fig. 6a), while only 9 % iNKT cells were IFNc? in
mice treated with the irrelevant aGC/sCD1d-anti-HER2
fusion protein. Importantly, after three treatments, per-
centages of IFNc-producing cells were similar whether
gated on total or on PD-1? iNKT cells (Fig. 6a), con-
firming that PD-1 up-regulation was not sufficient to block
the restimulation of iNKT cells. In view of their fast
transactivation by iNKT cells, NK cells were tested in the
same groups of mice (Fig. 6b). After three injections of
aGC, spleen NK cells also failed to produce IFNc, as a
consequence of iNKT cell anergy. In contrast, in mice
treated with either aGC/sCD1d-anti-CEA or aGC/sCD1d-
anti-HER2 fusion proteins, NK cells remained reactive, as
seen by increased IFNc production. The repeated activation
of NK cells upon treatment with the irrelevant fusion
protein aGC/sCD1d-anti-HER2 indicated that sustained
systemic activation of iNKT cells had occurred, although to
a weaker extent than with the tumor-targeted treatment.
Serum cytokines measured 1 h after the third injection also
reflected the prolonged reactivity of iNKT cells to tumor-
targeted recombinant CD1d proteins (Fig. 6c), as shown by
significant serum levels of IFNc and IL-4 in mice treated
Fig. 5 In vivo antitumor activity of aGC/sCD1d-anti-CEA fusion
protein. a Mice were grafted s.c. with 7 9 105 MC38-CEA tumor
cells. I.v. injections of PBS (untreated), or equimolar amounts of
aGC, aGC-loaded sCD1d, aGC/sCD1d-anti-HER2, and aGC/sCD1d-
anti-CEA were started 6 days later when all tumors were well
established and were repeated for a total of 5 injections as specified.
Tumors were measured every 2 days and the graph represents the
kinetic of tumor growth (mm3) as the mean of 7 mice per group.
***P \ 0.001 versus untreated group. b Ex vivo IFNc production by
spleen iNKT cells at the end of the antitumor experiment (day 22).
Splenocytes were isolated 1 h after the sixth injection of each
treatment and iNKT cells were stained with CD1d-tetramer-PE and
anti-CD3-FITC, and intracellularly with anti-IFNc-APC. Results are
expressed as the mean percentage of IFNc-producing iNKT of three
mice per group. ***P \ 0.001 versus all groups. c The same samples
as in b were analyzed for the expression of the co-inhibitory receptor
PD-1 on spleen iNKT cells. The graph represents the percentage of
PD-1 positive iNKT cells from three mice per group. **P \ 0.005,
***P \ 0.001, ****P \ 0.0001 versus untreated group
c
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with aGC/sCD1d-anti-CEA protein, while barely any
cytokines could be measured after three injections of aGC/
sCD1d-anti-HER2 protein. Regarding aGC as a free drug,
a single injection induced a fast release of IFNc and IL-4,
but almost no cytokine production was detected after three
injections, confirming the induction of iNKT cell anergy.
Most importantly, in the absence of MC38-CEA tumor
grafts, repeated treatments with aGC/sCD1d-anti-CEA
fusion protein did not lead to significant release of cyto-
kines, which did not differ from mice treated with the
irrelevant aGC/sCD1d-anti-HER2 protein (Fig. 6d). Alto-
gether, these results demonstrate the importance of tar-
geting CD1d to the tumor site to favor a strong and
prolonged reactivity of iNKT cells.
Fig. 6 Sustained activation of iNKT and NK cells upon repeated
injections of tumor-targeted aGC/sCD1d-anti-CEA. Mice bearing
MC38-CEA tumors were treated three times, following the same
protocol as in the tumor therapy experiments (Fig. 5), and splenocytes
were analyzed 1 h after the third injection. As a positive control for
IFNc production, a naı¨ve mouse was injected only once with aGC.
a Percentage of IFNc-producing cells gated on total (black bars) or
PD-1? (empty bars) iNKT cells. b Percentage of IFNc-producing NK
cells as gated on CD3-NK1.1?. c Cytokines were measured by CBA
in the sera of mice taken 1 h after the third treatments, as described in
a. Graphs show the concentration of IFNc (left panel) and IL-4 (right
panel). d Serum levels of IFNc and IL-4 were compared between
mice-bearing or not MC38-CEA tumors, and treated with targeted or
non-targeted aGC/sCD1d fusion proteins administered as in a. All
data are shown as the mean ± SEM of 3 mice per group, *P \ 0.01,
**P \ 0.005, ***P \ 0.001, ****P \ 0.0001
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Discussion
The present study demonstrates the therapeutic efficacy of
recombinant sCD1d-antitumor scFv fusion proteins via the
sustained activation of murine and human cytolytic iNKT
cells. The attractiveness of this strategy resides in two main
beneficial characteristics. First, recombinant CD1d proteins
have the capacity to keep iNKT cells reactive through
multiple stimulations, in contrast to their unresponsiveness
after repeated challenge by aGC-loaded APCs. Second, the
targeting of CD1d molecules to cancer cells by their fusion
to an antitumor scFv fragment efficiently redirects acti-
vated iNKT cells to the tumor site, promoting a local innate
immune response, including direct lysis of targeted tumors
by iNKT cells, release of large amounts of cytokines and
transactivation of NK cells, altogether leading to prolonged
antitumor effects.
So far, the therapeutic use of iNKT cells has been lim-
ited by their short-lived cytokine response to aGC stimu-
lation, followed by a long-term anergy [4, 17, 18]. Several
mechanisms have been proposed for the induction of iNKT
cell unresponsiveness, and the controversial results suggest
that multiple factors are likely involved. At first, the fast
and long-term up-regulation of PD-1 upon activation of
iNKT cells was proposed as the main mechanism since
their anergic state could be prevented or reverted by PD-1/
PD-L1 blockade and did not occur in PD-1 KO mice [[28],
[29]]. However, the exclusive role of PD-1 in the control of
iNKT cell anergy was not confirmed in all systems [30],
and the involvement of co-stimulation through CD28 or co-
inhibitory receptors such as BTLA was suggested [30–32].
In this respect, our present results also demonstrated the
strong and long-term up-regulation of PD-1 upon activation
of murine iNKT cells, which however did not correlate
with the state of anergy. Indeed, iNKT cells remained
reactive to multiple injections of recombinant CD1d fusion
proteins despite similar up-regulation of PD-1 as was found
on anergic iNKT cells after treatment with aGC as a free
drug. Clinical trials in cancer patients have preferred the
autologous transfer of aGC-pulsed DC, which showed
prolonged iNKT cell activation, as compared to the gly-
colipid alone [4, 11, 13, 14, 33]. However, a maximum of
two subsequent rounds of iNKT cell stimulations were seen
despite three to four autologous transfers of aGC-pulsed
DC in some studies, suggesting that iNKT cells became
progressively unresponsive to further challenge. Unfortu-
nately, in vitro experiments with human iNKT cells do not
allow monitoring the induction of anergy by aGC, likely
due to the presence of IL-2 required for the maintenance of
human and mouse iNKT cells in vitro. Indeed, IL-2 has
been shown to prevent or revert the state of anergy of
murine iNKT cells both in vivo and in vitro [18, 34].
However, it is interesting to note that around 70 % of
human iNKT cells were already expressing PD-1 when
tested ex vivo on total PBMC from healthy donors, prob-
ably resulting from previous in vivo antigen stimulations.
Since it is unlikely that the large majority of iNKT cells
present in normal donors are anergic, the expression of PD-
1 on activated human and mouse iNKT cells is probably
not sufficient to mediate iNKT cell unresponsiveness. So
far, the exact mechanism that mediates the aGC-induced
anergy of iNKT cells or, conversely, their prolonged
reactivity to recombinant aGC/CD1d fusion proteins
remains unclear.
Importantly, our data demonstrated a direct activation of
human iNKT cells by recombinant soluble CD1d proteins
in the absence of any APC, which excluded the possibility
of loss of aGC from the recombinant CD1d proteins and its
loading onto endogenous CD1d expressed by APCs. In this
regard, the capacity of a monomeric CD1d molecule to
activate iNKT cells seems to be unique to this antigen-
presenting molecule, as soluble MHC Class I and Class II
monomers were shown to be unable to activate antigen-
specific T cells, in contrast to dimeric and multimeric
forms [35, 36]. The question remains whether the iNKT
cell activation by monomeric aGC/sCD1d proteins is
peculiar to the strong agonist aGC and whether it would
not occur with a more physiological CD1d ligand. Never-
theless, activation of human iNKT cells by soluble aGC/
CD1d proteins remained significantly less efficient than
plastic-coated or tumor bound CD1d fusion proteins and
aGC-pulsed APCs, which likely resulted from the lack of
molecular CD1d aggregation in the absence of plastic or
cell surface, as well as from the absence of co-stimulation.
In support of this, systemic treatments of mice with un-
targeted aGC/sCD1d or irrelevant aGC/sCD1d-scFv fusion
proteins led to a two to threefold weaker release of cyto-
kines, as compared to treatment with the tumor-targeted
aGC/sCD1d-scFv protein. Rather than a drawback, the
lower potency of soluble monomeric CD1d molecules will
be rather favorable in limiting a potentially detrimental
systemic activation of iNKT cells, while promoting their
sustained activation when targeted at the tumor site.
The second attractive characteristic of our immuno-
therapy strategy is the targeting of recombinant CD1d
fusion proteins to tumors by fusion of the extracellular part
of CD1d to an antibody scFv fragment specific for a tumor
antigen. Indeed, the present data show both in vitro with
human iNKT cell clones and in vivo in a therapeutic mouse
tumor model that the strongest tumor inhibition is obtained
with tumor-targeted recombinant sCD1d-antitumor scFv
fusion protein as compared to an irrelevant sCD1d fusion
protein. This finding fits with the prerequisite of CD1d
expression by tumors to promote efficient iNKT cell-
mediated killing, which has been previously reported in
humans in the context of CD1d-expressing lymphomas
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[26, 37, 38], and in mice with tumor models transfected
with CD1d [39, 40]. In this context, our strategy using
CD1d-antitumor scFv fusion proteins opens the possibility
to target CD1d-negative tumors and render them suscep-
tible to iNKT cell attack. The effectiveness of this
approach was best demonstrated by the direct cytotoxicity
of human iNKT cell clones against tumor cells when
coated with the aGC/sCD1d-scFv fusion protein specific
for the tumor antigen expressed on their surface, while the
untargeted aGC/sCD1d-scFv was unable to induce antitu-
mor cytotoxic activity. More importantly, although iNKT
cells were strongly activated by aGC-pulsed APCs, such as
C1R-CD1d or moDCs, as seen by CD107a expression and
cytokine release, they rather killed the APCs and to a lesser
extent the tumor cells, indicating that bystander killing by
iNKT cells was inferior to the CD1d-mediated cytotoxicity.
These observations suggest that the strategy of iNKT cell
activation by autologous transfer of aGC-pulsed DCs, as
tested so far in clinical trials, may direct the intrinsic
cytotoxic activity of iNKT cells preferentially against the
transferred DCs and not against tumors. Because of the
relatively low numbers of peripheral iNKT cells in humans,
this aspect was probably not a major issue, and these
protocols of DC transfer have instead successfully induced
the immunomodulatory functions of iNKT cells, such as
the transactivation of NK and T cells. However, our results
in mice demonstrated that the stronger iNKT cell activation
by tumor-targeted sCD1d treatment also led to higher NK
cell activation, which are known to greatly participate in
tumor inhibition [19]. Therefore, the targeting of CD1d
molecules to the tumor site not only triggers iNKT-medi-
ated tumor lysis, but also favors local innate and adaptive
antitumor responses, as suggested by the accumulation of
iNKT, NK, and T cells at the tumor site [19]. The impor-
tance of tumor targeting and local activation of iNKT cells
was underlined by recent clinical trials in which aGC-
pulsed DC and/or ex vivo expanded iNKT cells were
delivered in the vicinity of the tumor [15, 33]. The best
clinical results were obtained in HNSCC patients in whom
aGC-pulsed DCs were administered via the nasal submu-
cosa and iNKT cells via the tumor-feeding arteries [15, 41].
In addition to the local delivery of iNKT cells, this
encouraging clinical benefit also demonstrated the need to
increase the numbers of iNKT cells by autologous transfer
of in vitro expanded iNKT cell lines, since the frequency of
iNKT cells is often very low or even undetectable in
advanced cancer patients [8, 42]. To this aim, recombinant
sCD1d-antitumor fusion proteins appear as promising
tools: first, in vitro to expand large numbers of human
iNKT cells for adoptive transfer, and second, in vivo to
redirect these transferred iNKT cells to the tumor site.
Finally, the efficient tumor targeting of CD1d molecules
requires the over-expression of a tumor antigen for which a
high-affinity antibody scFv has been developed. So far, we
have used two of the highest affinity existing scFv frag-
ments specific for the HER2 and CEA, which are often
over-expressed, respectively, in breast cancers and gastric
cancers. As alternatives to tumor-associated markers,
antigens over-expressed in the tumor stroma and/or neo-
vessels would be additional good candidates for the tar-
geting of CD1d molecules to the tumor site.
In conclusion, the present results propose and support
monomeric CD1d-scFv antitumor fusion proteins as a potent
tool to effectively harness iNKT cells against cancer.
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